Literature DB >> 16083827

Prognostic factors in primary central nervous system lymphomas.

Andrés J M Ferreri1, Michele Reni.   

Abstract

Efforts to identify survival predictors in primary central nervous system lymphoma (PCNSL) have produced isolated, unconfirmed observations in small retrospective and prospective series. Age and performance status are two unanimously accepted prognostic factors. These and other independent predictors of survival were used by the International Extranodal Lymphoma Study Group (IELSG) to establish a prognostic scoring system able to distinguish risk groups in PCNSL. The IELSG score will improve further with better knowledge of these malignancies, especially with the inclusion of molecular and pharmacogenetic variables able to identify lymphomas with different chemosensitivities or degrees of aggressiveness. In the years ahead, a well-established prognostic score will allow the separation of patients into risk groups, which could result in the application of risk-tailored therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083827     DOI: 10.1016/j.hoc.2005.05.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  9 in total

1.  Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions.

Authors:  Rachna Malani; Ankush Bhatia; Julia Wolfe; Christian Grommes
Journal:  Leuk Lymphoma       Date:  2019-01-10

2.  Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience.

Authors:  Jong Hyung Yoon; Hyoung Jin Kang; Hyery Kim; Ji Won Lee; June Dong Park; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

3.  Syndrome of inappropriate secretion of antidiuretic hormone as an initial sign of primary central nervous system lymphomas in the hypothalamus.

Authors:  Masahiro Oishi; Yasuhiko Hayashi; Yasuo Sasagawa; Nozomu Oikawa; Mitsutoshi Nakada
Journal:  Acta Neurol Belg       Date:  2022-06-18       Impact factor: 2.396

4.  Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large B-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts.

Authors:  Danhui Li; Shengjie Li; Zuguang Xia; Jiazhen Cao; Jinsen Zhang; Bobin Chen; Xin Zhang; Wei Zhu; Jianchen Fang; Qiang Liu; Wei Hua
Journal:  EPMA J       Date:  2022-07-15       Impact factor: 8.836

5.  Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Miaoxia He; Changjing Zuo; Jianjun Wang; Jianmin Liu; Binghua Jiao; Jianmin Zheng; Zailong Cai
Journal:  Neuro Oncol       Date:  2013-03-12       Impact factor: 12.300

Review 6.  Treatment of primary central nervous system lymphoma.

Authors:  Meltem Ekenel; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

Review 7.  Role of microRNAs in primary central nervous system lymphomas.

Authors:  Xin Yu; Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2016-03-16       Impact factor: 6.831

8.  Treatment of primary central nervous system lymphoma.

Authors:  Meltem Ekenel; Lisa M Deangelis
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

9.  Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study.

Authors:  Alexandra L Farrall; Justine R Smith
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.